Novel microfluidic electrochemical biosensor for rapid diagnosis of biomarkers

点击翻译按钮获取中文摘要

Immunosensors are very known among different types of biosensors for rapid diagnosis of biomarkers in bodilyfluids. The label-format of immunosensors allows for flexible implementation of biosensing in a wide range ofdetection schemes. However, these systems are limited in very high sensitive detection of minutes of moleculesin complex biological samples. There is also a trade-off in the time, cost and additional steps associated withincorporating reporter molecules into the label-based process. Moreover, the use of optical detection systems inpoint-of-care devices has one more constraint in detection of multiple biomarkers simultaneously in a singlemultiplexed biosensor as they require an external light source, optical transducer and other optical componentslike lenses and reflectors, which makes the detection system bulky and complex. Among various types oflabel-free detection techniques, the electrochemical sensing is the simplest to integrate, highly sensitive andmore compatible with multiplexing and integration into microfluidics, which makes it ideal for point-of-carediagnosis.In this work, we will develop an integrated and autonomous microfluidic-based biosensor for rapid detection ofbrain injury biomarkers. A new bonding technology will be developed to adhere electrodes to microfluidiclayers noninvasively to enable efficient performance of electrodes and point-of-care detection of biomarkers. Ifsuccessful, the microfluidic nano-biosensor proposed in this work will be used for rapid diagnosis of threedifferent biomarkers of brain injury in blood samples of patients in less than an hour. The expertise of theapplicant in microfluidics and biosensors ensures the success of this project.Sensoreal Inc. will benefit from label-free biosensors to extend the application of their technology for rapid andautomated detection of multiple biomarkers in human biological samples using a point-of-care diagnostictechnology. The lower cost and predictive point of care sensors will enable the rapid and large scale diseasescreening and facilitate monitoring the efficacy of therapeutics, therefore benefit the health system in Canada.